MAIA News

Four deals priced this past week, only two of which met the criteria to be included in our 2022 IPO stats. Biotech MAIA Biotechnology (MAIA) offered more shares and priced at the low end to raise $10 million at a $68 million market cap. MAIA’s lead candidate is expected to enter Phase 2 human trials in Australia and Europe in 2022 for NSCLC, and the company...read more

Seven IPOs raised a combined $228 million in the slowest July in what’s shaping up to be the slowest year for the IPO market in over a decade. Five of the seven offerings came from foreign issuers, led by Chinese fintech AMTD Digital....read more

MAIA Biotechnology, a Phase 2 biotech developing targeted immunotherapies for cancer, raised $10 million by offering 2 million shares at $5, the low end of the range of $5 to $7. The company offered 0.3 million more shares than anticipated. The company's lead candidate, THIO, is expected to enter Phase 2 human trials in Australia and Europe in 2022 for Non-Small Cell Lung Cancer...read more

Two small deals are scheduled to price in the week ahead as the IPO market stays on track to post its slowest year in over a decade. Mobile Global Esports (MGAM) plans to raise $17 million at an $82 million market cap. Operating...read more